We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TT:NYSETrane Technologies plc Analysis

Data as of 2026-05-06 - not real-time

$488.88

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Trane Technologies posted a solid first‑quarter earnings beat, with adjusted EPS surpassing consensus and bookings expanding, reinforcing the bullish momentum indicated by price trading above both the short‑term and medium‑term moving averages. The technical picture shows the stock in a bullish trend, supported by a strong support level near the 20‑day average, while the RSI remains in the upper‑mid range, suggesting continued buying pressure. However, the MACD histogram has turned negative and the price is approaching a notable resistance zone just below the 52‑week high, hinting at a potential short‑term pullback. Volume is on an upward trajectory, confirming investor interest despite the recent rally.
Valuation metrics reveal that the market price sits well above the DCF‑derived fair value, rendering the stock overvalued relative to intrinsic estimates. Nonetheless, the company’s robust ROE, healthy free cash flow, and modest dividend payout ratio support the sustainability of its dividend. The industrial sector’s exposure to climate‑related regulation adds a layer of regulatory risk, while the global footprint moderates geographic concentration. Overall, the fundamentals are strong, but the premium pricing and elevated volatility suggest a measured approach.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price near resistance after earnings beat
  • Bearish MACD histogram indicating possible pullback
  • Strong support at recent SMA levels

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Growing backlog and bookings providing visibility
  • Revenue and EPS growth outpacing industry peers
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Overvaluation relative to DCF fair value
  • High valuation multiples versus industry average
  • Exposure to climate‑related regulatory shifts

Key Metrics & Analysis

Financial Health

Revenue Growth6.00%
Profit Margin13.41%
P/E Ratio37.4
ROE36.63%
ROA11.34%
Debt/Equity53.60
P/B Ratio12.6
Op. Cash Flow$3.5B
Free Cash Flow$2.7B
Industry P/E30.6

Technical Analysis

TrendBullish
RSI62.5
Support$448.42
Resistance$503.47
MA 20$477.58
MA 50$449.74
MA 200$426.55
MACDBearish
VolumeIncreasing
Fear & Greed Index90.46

Valuation

Fair Value$190.08
Target Price$517.69
Upside/Downside5.89%
GradeOvervalued
TypeGrowth
Dividend Yield0.88%

Risk Assessment

Beta0.98
Volatility32.28%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.